US/UK/Canada

Share

About Us

Inhalation Sciences Sweden AB (publ.) develops and sells patented, highly innovative labtech equipment for inhalation research. Scientists using it can now know, with unprecedented accuracy, how particles behave in our lungs when we inhale them: whether new pollutants or life-saving drugs that power human development.

Pick a time period -
Tags ( Active)

Inhalation Sciences receives IRS order worth approximately EUR 117,000

Inhalation Sciences Sweden AB (ISAB) today announces that it has received an IRS (Inhalation Research Services) order valued at approximately EUR 117,000 (approximately SEK 1.3 million) from a new customer.The customer is a European-based pharmaceutical and biotechnology company with extensive experience in producing both generic and innovative medicines. ISAB will use its PreciseInhale® platform technology to generate high-quality preclinical study data. The study will involve in vivo testing - meaning the research is conducted in living organisms - to evaluate how the inhaled compound

Inhalation Sciences secures additional PreciseInhale® service orders worth SEK 350,000

Inhalation Sciences Sweden AB (ISAB) has secured new service orders totalling approximately SEK 350,000 for its proprietary PreciseInhale® platform. The orders originate from established customers within the global pharmaceutical industry.The repeat business underlines the sustained commercial relevance of ISAB’s technology in pharmaceutical inhalation research. Both clients have maintained an active collaboration with ISAB over an extended period, integrating PreciseInhale® as part of their ongoing research workflows. Manoush Masarrat, CEO of Inhalation Sciences, comments: “It is

Inhalation Sciences receives new IRS order for DissolvIt® worth approximately EUR 139,000

Inhalation Sciences Sweden AB (ISAB) today announces that it has received an order valued at approximately EUR 139,000 (approximately SEK 1.5 million) for an IRS (Inhalation Research Services) for DissolvIt® from a recurring customer and major international pharmaceutical company. The company is a global developer and manufacturer of complex generics and specialty medicines, with a strong presence in both established and emerging markets, that will use ISAB’s technology to generate high-quality preclinical data for inhaled drug formulations.The project includes DissolvIt® studies on several

Inhalation Sciences receives new IRS orders worth EUR 52,000 from global pharmaceutical companies

Inhalation Sciences Sweden AB (publ) has received several new Inhalation Research Service (IRS) orders from recurring global pharmaceutical companies with a total value of approximately EUR 52,000 (approximately SEK 554,000).The orders relate to the company´s technology platform PreciseInhale® and DissolvIt® designed to deliver controlled and high-precision inhalation exposures for preclinical research. “These orders confirm a continued strong interest in our technology from our existing customer base and leading pharmaceutical companies”, says Manoush Masarrat, CEO of Inhalation

Inhalation Sciences receives major IRS order for DissolvIt® from leading global pharma company

Inhalation Sciences Sweden AB (“ISAB”) has received a major Inhalation Research Services (IRS) order from a large global pharmaceutical company with commercial presence in more than 100 countries, including the US and Europe. The order value amounts to a total of EUR 224,555, corresponding to approximately SEK 2.45 million.The assignment covers advanced in vitro dissolution testing using ISAB’s proprietary DissolvIt® technology, in which several different inhalation formulations will be evaluated and compared to generate high‑precision data that support the customer’s continued development

Inhalation Sciences Presented FDA-Funded Study Results on DissolvIt® and the APRINHA Project at the DDL Conference

Inhalation Sciences AB (ISAB) yesterday presented previously announced positive data from the FDA-funded evaluation study of its advanced in vitro dissolution module, DissolvIt[®], at the annual Drug Delivery to the Lungs (DDL) Conference in Edinburgh.The results show that DissolvIt[®] generates pharmacokinetic (PK) data capable of predicting clinical plasma concentration profiles, demonstrating strong potential for its use in bioequivalence assessments of inhaled drugs. “It’s a breakthrough for Inhalation Sciences and a huge opportunity for companies looking to de-risk, accelerate

Inhalation Sciences receives purchase order worth 160 KEUR from international distributor for the US market

Inhalation Sciences AB (ISAB) has received a purchase order worth 160 KEUR (1.756 MSEK) from an international distributor for the US market. The new order is for the PreciseInhale® platform, ISAB's unique aerosol generation system. The end customer is a global pharmaceutical company based in the US.PreciseInhale® is unique within inhaled drug development as a ‘precision dosing’ system. Unlike standard ‘tower testing’ systems, it customizes the individual aerosol dose to individual test animals, achieving exceptionally high-precision and predictive data in the preclinical stages of inhaled

Inhalation Sciences hires advisors to evaluate potential acquirers of the company or the company's operations

Inhalation Sciences announced today that the company has engaged the international transaction advisor PharmaVentures LTD to evaluate existing contacts and initiate new ones with potential acquirers of the company's operations. The purpose of the assignment is to assess the possibility of realizing the highest possible shareholder value from Inhalation Sciences' world-leading patented technologies and extensive knowledge in inhalation research. The company expects to be able to conclude the process within 9-12 months.For many years, Inhalation Sciences has sold services and instruments

Inhalation Sciences receives IRS order from leading European university hospital

Inhalation Sciences Sweden AB (ISAB) has secured a new Inhalation Research Service (IRS) order for its innovative PreciseInhale® in vivo platform, designed to deliver controlled and high-precision inhalation exposures for preclinical research. The order value totals EUR 66,968, corresponding to approximately SEK 731,000.The order will support advanced research using intratracheal (IT) exposure in rats, enabling robust in vivo studies to better understand the impact of inhaled compounds. The client is a leading university hospital in Europe, renowned for pioneering research in oncology,

Inhalation Sciences to Present abstracts from the FDA-Funded Evaluation Study on DissolvIt® and the APRINHA Project at the 2025 DDL Conference

Inhalation Sciences AB (ISAB) today announced that both of its submitted abstracts have been accepted for presentation at the upcoming Drug Delivery to the Lungs (DDL) Conference in December. ISAB’s Chief Scientific Officer and founder, Assoc. Professor. Per Gerde and Director of Projects, PhD Maria Malmlöf, will present results from two major research initiatives, highlighting the company’s latest advances in inhalation drug development.This recognition underscores ISAB’s continued leadership in advancing cutting-edge research within inhaled drug development. Assoc. Professor. Per Gerde,

Inhalation Sciences receives service orders from recurring global pharma customers

Inhalation Sciences Sweden AB (ISAB) has received service orders valued at EUR 58,525 (approximately SEK 646,000) from two recurring clients - a global pharmaceutical company and a leading global generic drug manufacturer.The clients, who have been customers of ISAB for many years, continue to use ISAB’s inhalation research instruments on a regular basis and have consistently expressed strong satisfaction with the performance and reliability of ISAB’s technology. Manoush Masarrat, CEO of Inhalation Sciences, comments: “We are very pleased to once again be entrusted with orders from

University of Liège highlights the value of PreciseInhale® in advancing Inhalation Research

Inhalation Sciences (ISAB) is pleased to announce the continued success and positive feedback from its recurring user base, this time it is a long-standing client, the University of Liège, following the publication of new research utilizing the PreciseInhale® platform.The research, led by Professor Didier Cataldo, focused on the formulation and performance of a novel dry powder for inhalation, combining ciclesonide and indacaterol, two agents critical for treating asthma and chronic obstructive pulmonary disease (COPD). Over the course of one year, Professor Cataldo and his team have relied

Inhalation Sciences launches marketing campaign to increase awareness

Inhalation Sciences Sweden AB (ISAB or the company) today announces the start of a marketing campaign with the goal of increasing awareness and interest of its platform technology and cutting-edge services within inhaled drug development. The campaign will be implemented primarily via LinkedIn, the company’s website as well as in industry meetings and is designed to reach key stakeholders across the pharmaceutical industry as well as contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs).The campaign is based on two important drivers: the

Inhalation Sciences receives service order from recurring global pharmaceutical customer

Stockholm, July 1, 2025 - Inhalation Sciences Sweden AB (ISAB) today announces that the company has received a new service order from a recurring global pharmaceutical customer worth EUR 14,250 (158,600 SEK). The customer has previously invested in several of ISAB's advanced research instruments and has now expanded its collaboration by signing an additional service agreement and more service agreements are underway.The new agreement covers continued service and technical support for the customer's existing installations of ISAB's patented research platform PreciseInhale®, which is used in

Inhalation Sciences AB (publ) releases Annual Report 2024

Inhalation Sciences AB announces that its Annual Report for 2024 is now available on the company's website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/CEO comments 2024 has been a year where customers continued to show interest in our services, but also a year characterized by slow decisions on our offers and where many customers continued to have challenges in financing their development projects. Something we experienced throughout the year, resulting in lower turnover and sales. Our assessment for 2025 is that the customers'

Inhalation Sciences appoints Ulf Wedenberg as Chief Commercial Officer (CCO)

Stockholm, May 27, 2025 - Inhalation Sciences Sweden AB (ISAB) has recruited Ulf Wedenberg as its new Chief Commercial Officer (CCO). The recruitment comes at a crucial time for the company, where international interest in ISAB's unique inhalation technologies and CRO services has increased significantly - especially after the recently presented FDA study that further confirmed the company's scientific and regulatory relevance.Ulf Wedenberg has over 25 years of experience from leading roles in sales, marketing and business development in the pharmaceutical and medical device sector. He has

Inhalation Sciences Signs Strategic Agreement with U.S.-based BioLum Sciences, expanding U.S. Presence & Commercial Reach to Advance In Vitro Respiratory Research

Stockholm, May 22, 2025 - Inhalation Sciences AB (ISAB) today announces that the company has entered into a Master Service Agreement (MSA) with the US-based company BioLum Sciences, active in inhalation research and diagnostics. The collaboration aims to strengthen ISAB's commercial presence in the US, increase the availability of the company's technologies and meet the growing demand for advanced in vitro models in line with new regulatory guidelines from the FDA.BioLum Sciences, based in Dallas, Texas, is an innovative company specializing in the development of novel inhalation diagnostic

Inhalation Sciences receives new IRS orders from returning customers – increased demand in line with regulatory requirements

Stockholm, May 8, 2025 - Inhalation Sciences AB (ISAB) today announces that the company has received two new orders for a total value of EUR 27,400. The orders come from returning customers who have chosen to re-order IRS (Inhalation Research Services) studies via ISAB's advanced exposure platforms PreciseInhale® and DissolvIt® for ongoing preclinical inhalation studies.In recent weeks, ISAB has received several requests and these two formal orders reinforce the picture of a growing need for accurate and regulatory relevant data in inhalation research. A key driver behind this

Inhalation Sciences AB reports positive primary and secondary study results in the FDA-funded study of DissolvIt® and receives approval from the FDA to publish the study results

Stockholm, Sweden - April 24, 2025 - Inhalation Sciences AB (ISAB) has completed the FDA-funded study[1] of DissolvIt® (ISAB's proprietary unique methodology for dissolution testing of inhaled drugs) with successful results where all primary and secondary study objectives were confirmed to be met. After final minor amendments, the study report has now been approved by the FDA for publication.“We are very pleased with the results of this comprehensive groundbreaking study that met both our primary and secondary study objectives and confirms our development hypothesis as well as previous

Inhalation Sciences receives new order worth 41,000 Euro from returning big pharma customer

Stockholm, Sweden – April 15, 2025 – Inhalation Sciences AB (ISAB) has received a purchase order from a recurring global customer. The order, valued at 41,000 EUR, includes additional instruments and complementary equipment for advanced inhalation research.This repeat business strengthens ISAB’s long-term relationship with the customer and further confirms the trust in the company’s technology and expertise within inhalation research. "The fact that a global player once again chooses to invest in our technology is a strong validation of the quality and precision our systems deliver. We

Inhalation Sciences well-positioned as FDA emphasizes dissolution testing for inhalation studies

Stockholm, Sweden – March 3, 2025 – Inhalation Sciences AB (ISAB), a leader in inhalation research and drug development, welcomes the U.S. Food and Drug Administration’s (FDA) latest guidelines[1], which establish dissolution testing as a key method for evaluating inhaled drug products. The updated recommendations reinforce the relevance of ISAB’s proprietary DissolvIt® system, which has already been the focus of an FDA-financed study aimed at improving regulatory science in inhalation drug development.The new FDA guidelines highlight dissolution testing as a recommended approach for

Inhalation Sciences AB (publ) releases Q4 / Year-End Report 2024

(Stockholm, Sweden, 28 February 2025) Inhalation Sciences AB announces that its Q4 / Year-End Report for 2024 is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiellarapporter/CEO statement 2024 was a year in which customers continued to show interest in our services, but also a year characterized by slow decisions on our offers and where many customers continued to face challenges in financing their development projects. This is something we experienced throughout the year, resulting in lower turnover and sales.

Inhalation Sciences’ launch of the XposeALI[®] in vitro module with microperfusion

(Stockholm, Sweden, 13 January 2025) Inhalation Sciences (ISAB) announces its plans to launch the company’s XposeALI[®] in vitro exposure module, now with microperfusion. The development work was undertaken in 2024 with the final testing and validation being performed in a study co-financed with one of the company’s longstanding global pharmaceutical customers.By adding the option of microperfusion to the XposeALI system, the mode-of-action of inhaled substances in the lungs can now be simulated in vitro with higher relevance. The unique capability of the XposeALI system to deliver various

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe